Skip to main content
. 2023 Jul 14;12(5):1491–1515. doi: 10.1007/s40120-023-00518-0

Fig. 2.

Fig. 2

Timeline of ofatumumab key publications and approvals. EMA European Medicines Agency, FDA US Food and Drug Administration, IV intravenous, RA rheumatoid arthritis, RMS relapsing multiple sclerosis, SC subcutaneous